The resurgence of covalent drugs

@article{Singh2011TheRO,
  title={The resurgence of covalent drugs},
  author={Juswinder Singh and Russell C. Petter and Thomas A. Baillie and Adrian Whitty},
  journal={Nature Reviews Drug Discovery},
  year={2011},
  volume={10},
  pages={307-317}
}
Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. This Review surveys the prevalence and pharmacological advantages of… 

Figures, Tables, and Topics from this paper

10 years into the resurgence of covalent drugs.
  • E. D. Vita
  • Medicine, Chemistry
    Future medicinal chemistry
  • 2020
TLDR
An overview of the milestones hit with targeted covalent inhibitors, as well as the promise and the needs of current research, are presented and many questions remain unexplored in this branch of precision medicine.
Covalent Inhibition in Drug Discovery
TLDR
This review surveys enzymes that can be targeted by covalent inhibitors for the treatment of human diseases, focusing on protein kinases, RAS proteins, and a few other enzymes that have been studied extensively as targets for covalents.
Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.
TLDR
Evidence suggests that there is a reduced risk for the development of resistance against covalent drugs, which is a major challenge in areas such as oncology and infectious disease.
Recent advances in the development of covalent inhibitors.
TLDR
The purpose of this focused review is to provide an understanding of the development of covalent inhibitors by describing their inherent characteristics, possibilities, and limitations based on their mechanistic differences from noncovalent inhibitor.
Drug discovery considerations in the development of covalent inhibitors.
TLDR
A review will highlight a number of methods and tools useful for prosecuting covalent inhibitor drug discovery programs.
Covalent inhibitors design and discovery.
TLDR
The goal of this article is to provide an overview of the field and to outline good practices that are needed for the proper assessment and development of covalent inhibitors as well as a good understanding of the potential and limitations of current computational methods for the design of cavalent drugs.
Covalent binders in drug discovery.
TLDR
This perspective covers the tenets and applications of covalent binders in terms of understanding how to tune electrophilicity to selectively target specific residues.
Drug discovery for a new generation of covalent drugs
TLDR
The review examines potential reason(s) for the excellent safety record of marketed covalent agents and advanced clinical candidates for emerging therapeutic targets and significant emphasis is placed on proteomic techniques and chemical/biochemical reactivity assays that aim to provide a systematic rank ordering of pharmacologic selectivity relative to off-target protein reactivity of covalents.
Structure-based design of targeted covalent inhibitors.
TLDR
This tutorial review introduces the broader concept of covalent inhibition, discusses the potential benefits and challenges of such an approach, and provides an overview of the current status of the field.
Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation.
TLDR
This review briefly reflects on the history of selective covalent targeting, provides a comprehensive overview of emerging developments from a chemical biology stand-point, and reflects on efforts to validate irreversible covalENT ligands, expand the scope of targets, and discover new ligands and warheads.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 96 REFERENCES
Targeted covalent drugs of the kinase family.
TLDR
Recent pre-clinical and clinical advances with targeted covalent kinase inhibitors, and the potential for broader application of the approach are reviewed.
Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.
This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid
5‐FLUOROURACIL: A PHARMACOLOGICAL PARADIGM IN THE USE OF CYTOTOXICS
1. Painstaking progress in drug development is well illustrated by 5‐fluorouracil (5FU), originally designed 40 years ago as a fluorinated analogue of the naturally occurring base uracil. Innovative
Drug-target residence time: critical information for lead optimization.
TLDR
To improve the correlation between the in vitro and in vivo activity of drugs, measurements of drug-target residence time must be incorporated into the drug discovery process.
Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions.
TLDR
The approaches that are currently available for addressing this issue during the lead optimization phase of drug discovery, their limitations, and future scientific directions that have the potential to address these limitations are discussed.
[Safety and interactions of proton pump inhibitors: lessons learned in millions of patients].
TLDR
The present article reviews PPI administration in special, currently debated situations, such as in pregnant or breastfeeding women, and recommends the use of omeprazole or clopidogrel in these situations.
Drug–target residence time and its implications for lead optimization
Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromolecules by low-molecular-mass drugs. The binding of drugs to their macromolecular
Targeting proteases: successes, failures and future prospects
  • B. Turk
  • Biology, Medicine
    Nature Reviews Drug Discovery
  • 2006
TLDR
The status of human protease research and prospects for future protease-targeted drugs are reviewed, with reference to some key examples where protease drugs have succeeded or failed.
Mechanistic basis of enzyme-targeted drugs.
TLDR
The variety of inhibition mechanisms for enzyme-targeted drugs are reviewed, an enzyme target database for drugs currently marketed in the United States is established, and advanced methods for determining transition-state structure now offer the opportunity for direct drug design without resorting to expensive random testing campaigns.
Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology.
  • T. Baillie
  • Chemistry, Medicine
    Chemical research in toxicology
  • 2006
TLDR
Research leading to a deeper insight into mechanistic aspects of toxicities caused by reactive drug metabolites will aid greatly in the rational design of drug candidates with superior safety profiles and represents a challenging and exciting opportunity for chemical toxicology.
...
1
2
3
4
5
...